Why the study?
Does metoprolol attenuate post-infarct remodeling and improve myocardial energy metabolism and function in a rat model of post-infarct congestive heart failure?
Does metoprolol attenuate post-infarct remodeling and improve myocardial energy metabolism and function in a rat model of post-infarct congestive heart failure?
In a rat model of post-infarct CHF, metoprolol attenuates structural remodeling without improving myocardial energy metabolism or function, suggesting these improvements are not prerequisites for anti-remodeling effects.
Answers are grounded in this paper and cite their sources.
Metoprolol may attenuate post-MI remodeling independently of energetics or function in rats; leaves open mechanisms and clinical translation in HF.
OBJECTIVE: To investigate in vivo effects of long-term selective beta1-blockade on cardiac energy metabolism, remodelling, function and plasma cytokines in a rat model of post-infarct congestive heart failure (CHF). METHODS: Myocardial infarction (MI) was induced in male rats by ligation of the left coronary artery. Three different groups of rats were studied, MI rats treated with metoprolol (n=17), MI rats treated with saline (n=14) and sham-operated rats (n=12). The treatment with metoprolol 1 mg/kg/h was initiated in the third week post-infarct for a period of 6 weeks. All rats were investigated non-invasively with volume-selective 31P magnetic resonance spectroscopy and echocardiography for evaluation of left ventricular (LV) energy metabolism, morphology and function. Plasma concentration of IL-1beta and IL-6 and density of beta-adrenergic receptors were analyzed. RESULTS: Metoprolol attenuated the increase in LV dimensions and volumes. Treatment with metoprolol had no effect on PCr/ATP and LV function. Plasma level of IL-1beta was higher and IL-6 was lower in the metoprolol group. Density of beta-adrenergic receptors was similar in all three groups. CONCLUSION: Selective beta1-blockade in rats with chronic CHF attenuates post-infarct structural remodelling, without concomitant improvement in myocardial energy metabolism and function. Improvements in myocardial energy metabolism and function do not precede and are not a prerequisite for an anti-remodelling effect of beta1-blockade in the setting of chronic CHF.
No takes yet. Share an insight, caveat, or question.
Ömerovic et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: